TABLE 1.
Baseline characteristics and response to treatments
| Feature | Patients with ADC‐BCMA pretreatment a | Patients without ADC‐BCMA pretreatment | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient number | 1 | 2 | 3 | 4 | 5 | 7 | 10 | 6 | 8 | 9 | 11 |
| STOMP treatment | XVd | XVd | XVd | XPd | XPd | XKd | XPd | XPd | XPVd | XPEd | XKd |
| ISS stage at initial diagnosis | I | Unknown | III | II | I | II | I | Unknown | III | II | Unknown |
| Diagnosis to 1st STOMP dose (yr) | 5.2 | 6.3 | 12.8 | 8.4 | 6.9 | 5.7 | 7.8 | 4.8 | 2.3 | 8.5 | 8.7 |
| High risk at diagnosis/Screening b | N/N | N/N | N/Y | N/Y | N/N | N/Y | Y/Y | N/N | Y/N | N/N | N/Y |
| Number of prior lines of therapy | 5 | 6 | 8 | 10 | 9 | 6 | 4 | 5 | 5 | 7 | 5 |
| Prior MM therapies (type) | V,R,P | V,K,R,P | V,R,P,D (Quad) | V,K,R,P,D (Penta) | V,K,R,P,D (Penta) | V,K,R,P,D (Penta) | V,R,D (Triple) | V,K,N,R,P,D (Penta) | V,K,R,P,D (Penta) | V,K,R,P,D (Penta) | V,K,N,T,R,PD (Penta) |
| Refractory MM therapies (type) c | R | V,K,R,P | V,R,P | V,K,R,P,D (Penta) | K,R,P,D (Quad) | P,D | V,D | K,N,R,P | K,R,P,D (Quad) | K,R,P,D (Quad) | R,P,D |
| Prior ASCT | Y | Y | Y | Y | N | Y | Y | Y | N | Y | Y |
| Anti‐BCMA in immediate prior line | Y | Y | N | N | Y | Y | Y | Y | Y | N | Y |
| Most recent anti‐BCMA therapy | belantamab mafodotin | belantamab mafodotin | belantamab mafodotin | belantamab mafodotin | MEDI2228 | belantamab mafadotin + pembrolizumab | belantamab mafodotin | idecabtagene vicleucel ± daratumumab | SEA‐BCMA ± dex | BCMA BiTE | idecabtagene vicleucel |
| Duration of most recent prior anti‐BCMA regimen (mo) | 1.5 | 0.8 | 1.1 | 4.3 | 1.7 | 1.4 | 24.9 | 2.7 | 1.4 | 1.7 | 5.8 |
| Best response on most recent prior anti‐BCMA | PR | SD | SD | VGPR | PD | SD | VGPR | PR | SD | Unknown | PR |
| Time from end of anti‐BCMA to 1st STOMP dose (mo) | 0.8 | 1.0 | 7.4 | 35.2 | 0.2 | 1.1 | 1.0 | 1.3 | 1.0 | 14.2 | 2.6 |
| Best response on STOMP | PR | SD | MR | SD | PR | PR | PR | VGPR | PR | MR | VGPR |
| Duration of STOMP treatment (mo) | 7.9 | 6.0 | 8.1 | 1.4 | 2.9 | 15.8 d | 12.2 d | 15.1 | 12.9 | 1.4 | 13.1 d |
Abbreviations: ADC, antibody‐drug conjugates; ASCT, autologous stem cell transplant; BCMA, B‐cell maturation antigen; D, daratumumab; dex, dexamethasone; IMiD, immunomodulatory drug; ISS, International Staging System; K, carfilzomib; MM, multiple myeloma, mAb, monoclonal antibody; mo, months; MR, minimal response; N, ixazomib; P, pomalidomide; PD, progressive disease; PI, proteasome inhibitor; PR, partial response; R, lenalidomide; SD, stable disease; STOMP, Selinexor and backbone treatments of multiple myeloma patients; T, thalidomide;V, bortezomib; VGPR, very good partial response; XKd, selinexor + carfilzomib + dex; XPd, selinexor + pomalidomide + dex; XPVd, selinexor + pomalidomide + bortezomib + dex; XVd, selinexor + bortezomib + dex; XPEd, selinexor + pomalidomide + elotuzumab + dex; yr, years.
Patients #1‐5, 7, and 10 were treated with ADC anti‐BCMA therapies.
High‐risk MM includes the presence of del(17p), t(4;14), t(14;16), gain 1q, or extramedullary myeloma at screening.
Prior therapy/Refractory therapy type: triple, MM treated with or refractory to PI, IMiD, anti‐CD38 mAb; Quad, MM treated with or refractory to 2 PI, 1 IMiD, and 1 anti‐CD38 mAb OR to 1 PI, 2 IMiD, and 1 anti‐CD38 mAb; Penta, MM refractory to ≥2 PI, ≥2 IMiD, ≥1 anti‐CD38 mAb.
Ongoing therapy at data cutoff.